Oxford Ledge
Search
No licensed closing price on file for ERAS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Erasca, Inc. (NASDAQ: ERAS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:14 UTC.
Erasca is a clinical-stage precision oncology company developing therapies to treat cancers driven by mutations in the RAS and MAPK signaling pathway. The company pursues three therapeutic strategies: targeting upstream and downstream pathway nodes, directly targeting RAS through molecular glue and inhibitor approaches, and blocking escape routes that allow tumors to develop resistance. The company's pipeline includes two clinical-stage programs—ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor—as well as ERAS-12, a discovery-stage program targeting EGFR.
Summarized from Erasca, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
Charts, 10-year financials, peer comparison, screening and portfolio tracking for ERAS and 5,000+ tickers.
Create a free account — keep ERASGET /api/data?ticker=ERAS
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt